Sojournix is a clinical stage biopharmaceutical company focused on developing and commercializing novel therapies for the treatment of women’s health and neuroendocrine disorders.
We are developing SJX-653, a novel and selective neurokinin-3 (NK3) antagonist as a once-daily non-hormonal therapy for moderate to severe vasomotor symptoms (VMS or hot flashes) due to menopause. An estimated 6,000 U.S. women reach menopause eve...
Sojournix is a clinical stage biopharmaceutical company focused on developing and commercializing novel therapies for the treatment of women’s health and neuroendocrine disorders.
We are developing SJX-653, a novel and selective neurokinin-3 (NK3) antagonist as a once-daily non-hormonal therapy for moderate to severe vasomotor symptoms (VMS or hot flashes) due to menopause. An estimated 6,000 U.S. women reach menopause every day (over two million per year) and the majority of these women experience vasomotor symptoms.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.